Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07253064

Study Comparing Eye Growth Over Time in Children Using Two Myopia Control Lenses

The goal of this clinical trial is to investigate the short-term changes in the eye structure while wearing two types of lenslet-based myopia control lenses over a period of 6 months in children aged 6 to 13 years with myopia. The main question it aims to answer is:

* How the eye responds, at each timepoint, to the two myopia control lenses by evaluating:

1. Change in axial length 2. Change in choroidal thickness

Participants will: * Wear the study spectacles * Visit Essilor R&D Centre for follow-up sessions

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

6 year–13 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Essilor R&D Centre Singapore

Singapore

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Volunteer participant
  • Informed consent of parent or guardian and assent of participant
  • Age: Equal to or greater than 6 years but not older than 13 years at the time of informed consent and assent.
  • Refractive error (manifest refraction):
  • Equal or less than -0.50 D or equal or greater than -4.75D.
  • Astigmatism should be less than or equal to 2.00D.
  • Anisometropia should be less than or equal to 1.00D
  • Best corrected visual acuity: Better than 0.2 logMAR in each eye
  • Willingness and ability to:
  • participate in trial for at least 6 months.
  • attend scheduled visits.
  • not to be involved in other myopia control treatments concurrently.
  • No history of any myopia control interventions (i.e., myopia control spectacle lenses, myopia control contact lenses, orthokeratology lenses or atropine, etc.)

Exclusion criteria

  • History or presence of:
  • An ocular disease
  • Strabismus
  • Amblyopia
  • Currently or previously on any myopia control interventions (i.e., myopia control spectacle lenses, myopia control contact lenses, orthokeratology lenses or atropine, etc.)

Treatment and study plan

MCL 1

Device

Myopia Control Lens 1 (MCL 1) is an ophthalmic lens intended to slow down eye growth in children. This lens will be dispensed to either the right or left eye and will be worn by the participant for a period of 6 months.

MCL 2

Device

Myopia Control Lens 2 (MCL 2) is an ophthalmic lens intended to slow down eye growth in children. This lens will be dispensed to either the right or left eye and will be worn by the participant for a period of 6 months.

Primary outcomes

  1. Change in Axial Length

    Time frame: Baseline, 1 hour post-dispense, 1 week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, and 24 weeks post-dispense.

Secondary outcomes

  1. Change in Choroidal Thickness

    Time frame: Baseline, 1 hour post-dispense, 1 week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, and 24 weeks post-dispense.

Sponsors and collaborators

Lead sponsor

Essilor International

Industry

Registry information

Official study title

A Monocentre, Randomized, Contralateral Trial to Study the Effect of Temporal Changes in Ocular Biometry of Two Myopia Control Lenses

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Nov 28, 2025
Registry last updated
Jun 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.